The reaffirmation of an Outperform rating and a $9 price target by a reputable analyst like Leland Gershell from Oppenheimer is likely to instill confidence among investors and could positively influence Trevi Therapeutics' stock price in the short term. Analyst ratings, especially those that are maintained or upgraded, tend to have a significant impact on investor sentiment and can lead to price movements.